Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485495 | 0.86 | KCNQ2 (0.47) | KCNQ2KDM4EMAPTMMP2MMP13 | |
| SCHEMBL3485857 | 0.85 | PPARG (0.50) | KCNQ2KDM4EMAPTF10PTGDR2 | |
| SCHEMBL3485512 | 0.85 | KCNQ2 (0.62) | KCNQ2CA12CA1CA2CA9 | |
| SCHEMBL3485556 | 0.83 | CNR2 (0.52) | KCNQ2KDM4EMAPTMMP2MMP13 | |
| SCHEMBL13435458 | 0.82 | KCNQ2 (0.48) | KCNQ2CA12CA1CA2CA9 | |
| SCHEMBL3484832 | 0.82 | KCNQ2 (0.48) | KCNQ2KDM4EMAPTMMP2MMP13 | |
| SCHEMBL3485770 | 0.81 | KCNQ2 (0.42) | KCNQ2KDM4EMMP2MMP13F10 | |
| SCHEMBL3485725 | 0.81 | PTGDR2 (0.43) | KCNQ2KDM4EF10PTGDR2CNR2 | |
| SCHEMBL16933517 | 0.80 | RORC (0.53) | RORCPTGDR2CNR2 | |
| SCHEMBL3485915 | 0.78 | CYP26A1 (0.46) | KCNQ2KDM4EMAPTPTGDR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | CDK5 903/4885CDK5R1 758/4885KCNQ2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.